The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that propose to develop and validate physical, chemical and biochemical approaches for measuring properties and dynamics of the three-dimensional organization of the genome that cannot be measured adequately using existing methodologies.
The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that propose to develop and validate physical, chemical and biochemical approaches for measuring properties and dynamics of the three-dimensional organization of the genome that cannot be measured adequately using existing methodologies.
This Funding Opportunity Announcement (FOA) encourages the translation of technologies for biomedical or behavioral research from academic and other non-small business research sectors to the marketplace. Small Business Concerns (SBCs) are encouraged to submit Small Business Innovation Research (SBIR) grant applications that propose to further develop, make more robust, and make more user-friendly such technologies in preparation for commercial dissemination. It is expected that this activity will require partnership and close collaboration between the original developers of these technologies and applicant SBCs, which may be accomplished in any of a number of ways, including the use of multiple principal investigators.
This Funding Opportunity Announcement (FOA) will support rigorous, pre-clinical studies that establish the rationale for a clinical trial, where the hypothesis originates from use of a published or publicly available method for identifying new indications for existing drugs or biologics (therapeutics). The goal of an individual project will be to explore the potential new use of an existing investigational, phase 2a-ready, or FDA-approved drug or licensed biologic; a pre-clinical study funded through this initiative will serve as a use case to demonstrate the utility of an independent crowdsourcing effort or of a computational algorithm to predict new uses of a drug or biologic.
This FOA encourages research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as "high priority" genetic conditions where screening may be possible in the near future. Demonstrating the benefits of treatment is often a primary criterion for including a condition on a newborn screening panel; therefore, this FOA, a "high priority" condition is one where screening is not currently recommended but would significantly benefit from early identification and treatment. Also listed under R03
The United States Environmental Protection Agency (EPA), as part of its Science to Achieve Results (STAR) program, is seeking applications proposing research to support the development of improved science-based human health and environmental risk assessments of new biotechnology products, including those developed through synthetic biology, genome editing, and metabolic engineering.
The DOE SC program in Biological and Environmental Research (BER), hereby announces its interest in receiving applications for research in developing computational approaches that can integrate large, disparate data types from multiple and heterogeneous sources, such as those used in the Genomic Science program (GSP) (http://genomicscience.energy.gov). Research supported by awards resulting from this FOA will promote human understanding of the natural world through analysis of high-throughput biological systems data. BER has an ongoing mission of improving translation from the molecular to cellular realm within scientific disciplines supported by DOE.
The objective of this award is to provide additional career development support for outstanding Respiratory Therapists (RTs) who conduct research (clinical or translational), including detection, inhalation therapies, clinical care, diagnostics, and therapeutic tools in alpha-1 antitrypsin deficiency (AATD)-related lung disease.
Group items tagged 
